27117874|t|A Randomized Controlled Noninferiority Trial of Single Dose of Oral Dexamethasone Versus 5 Days of Oral Prednisone in Acute Adult Asthma
27117874|a|Oral dexamethasone demonstrates bioavailability similar to that of oral prednisone but has a longer half-life. We evaluate whether a single dose of oral dexamethasone plus 4 days of placebo is not inferior to 5 days of oral prednisone in treatment of adults with mild to moderate asthma exacerbations to prevent relapse defined as an unscheduled return visit for additional treatment for persistent or worsening asthma within 14 days. Adult emergency department patients (aged 18 to 55 years) were randomized to receive either a single dose of 12 mg of oral dexamethasone with 4 days of placebo or a 5- day course of oral prednisone 60 mg a day. Outcomes including relapse were assessed by a follow-up telephone interview at 2 weeks. One hundred seventy-three dexamethasone and 203 prednisone subjects completed the study regimen and telephone follow-up. The dexamethasone group by a small margin surpassed the preset 8% difference between groups for noninferiority in relapse rates within 14 days (12.1% versus 9.8%; difference 2.3%; 95% confidence interval -4.1% to 8.6%). Subjects in the 2 groups had similar rates of hospitalization for their relapse visit (dexamethasone 3.4% versus prednisone 2.9%; difference 0.5%; 95% confidence interval -4.1% to 3.1%). Adverse effect rates were generally the same in the 2 groups. A single dose of oral dexamethasone did not demonstrate noninferiority to prednisone for 5 days by a very small margin for treatment of adults with mild to moderate asthma exacerbations. Enhanced compliance and convenience may support the use of dexamethasone regardless.
27117874	2	44	Randomized Controlled Noninferiority Trial	T062	C0206035
27117874	48	59	Single Dose	T081	C0178602
27117874	63	81	Oral Dexamethasone	T200	C0360528
27117874	91	95	Days	T079	C0439228
27117874	99	114	Oral Prednisone	T200	C3216040
27117874	124	129	Adult	T100	C0001675
27117874	130	136	Asthma	T047	C0004096
27117874	137	155	Oral dexamethasone	T200	C0360528
27117874	156	168	demonstrates	T052	C3687625
27117874	169	184	bioavailability	T081	C0005508
27117874	185	192	similar	T080	C2348205
27117874	204	219	oral prednisone	T200	C3216040
27117874	237	246	half-life	T079	C0018517
27117874	270	281	single dose	T081	C0178602
27117874	285	303	oral dexamethasone	T200	C0360528
27117874	304	308	plus	T169	C0332287
27117874	311	315	days	T079	C0439228
27117874	319	326	placebo	T122	C1696465
27117874	334	342	inferior	T082	C0542339
27117874	348	352	days	T079	C0439228
27117874	356	371	oral prednisone	T200	C3216040
27117874	375	384	treatment	T169	C1522326
27117874	388	394	adults	T100	C0001675
27117874	400	404	mild	T033	C0581124
27117874	408	416	moderate	T033	C0581125
27117874	417	437	asthma exacerbations	T033	C0349790
27117874	441	448	prevent	T169	C1292733
27117874	449	456	relapse	T067	C0035020
27117874	471	482	unscheduled	T079	C3854240
27117874	500	520	additional treatment	T033	C1706712
27117874	525	535	persistent	T047	C3266628
27117874	539	548	worsening	T080	C0332271
27117874	549	555	asthma	T047	C0004096
27117874	566	570	days	T079	C0439228
27117874	572	577	Adult	T100	C0001675
27117874	578	598	emergency department	T073,T093	C3840745
27117874	599	607	patients	T101	C0030705
27117874	609	613	aged	T032	C0001779
27117874	623	628	years	T079	C0439234
27117874	635	645	randomized	T062	C0034656
27117874	649	656	receive	T080	C1514756
27117874	666	677	single dose	T081	C0178602
27117874	690	708	oral dexamethasone	T200	C0360528
27117874	716	720	days	T079	C0439228
27117874	724	731	placebo	T122	C1696465
27117874	740	743	day	T079	C0439228
27117874	744	750	course	T079	C0750729
27117874	754	769	oral prednisone	T200	C3216040
27117874	778	781	day	T079	C0439228
27117874	783	791	Outcomes	T169	C1274040
27117874	792	801	including	T169	C0332257
27117874	802	809	relapse	T067	C0035020
27117874	815	823	assessed	T052	C1516048
27117874	829	858	follow-up telephone interview	T058	C0178941
27117874	864	869	weeks	T079	C0439230
27117874	875	896	hundred seventy-three	T081	C0392762
27117874	897	910	dexamethasone	T109,T121	C0011777
27117874	919	929	prednisone	T109,T121,T125	C0032952
27117874	930	938	subjects	T096	C0681850
27117874	939	948	completed	T080	C0205197
27117874	971	990	telephone follow-up	T058	C0178941
27117874	996	1009	dexamethasone	T109,T121	C0011777
27117874	1010	1015	group	UnknownType	C0681860
27117874	1058	1068	difference	T080	C1705242
27117874	1077	1083	groups	UnknownType	C0681860
27117874	1088	1102	noninferiority	T080	C0205556
27117874	1106	1113	relapse	T067	C0035020
27117874	1114	1119	rates	T081	C1521828
27117874	1130	1134	days	T079	C0439228
27117874	1155	1165	difference	T080	C1705242
27117874	1176	1195	confidence interval	T081	C0009667
27117874	1212	1220	Subjects	T096	C0681850
27117874	1230	1236	groups	UnknownType	C0681860
27117874	1249	1254	rates	T081	C1521828
27117874	1258	1273	hospitalization	T058	C0019993
27117874	1284	1291	relapse	T067	C0035020
27117874	1292	1297	visit	T058	C1512346
27117874	1299	1312	dexamethasone	T109,T121	C0011777
27117874	1325	1335	prednisone	T109,T121,T125	C0032952
27117874	1342	1352	difference	T080	C1705242
27117874	1363	1382	confidence interval	T081	C0009667
27117874	1399	1413	Adverse effect	T080	C1280500
27117874	1414	1419	rates	T081	C1521828
27117874	1453	1459	groups	UnknownType	C0681860
27117874	1463	1474	single dose	T081	C0178602
27117874	1478	1496	oral dexamethasone	T200	C0360528
27117874	1505	1516	demonstrate	T052	C3687625
27117874	1517	1531	noninferiority	T080	C0205556
27117874	1535	1545	prednisone	T109,T121,T125	C0032952
27117874	1552	1556	days	T079	C0439228
27117874	1584	1593	treatment	T169	C1522326
27117874	1597	1603	adults	T100	C0001675
27117874	1609	1613	mild	T033	C0581124
27117874	1617	1625	moderate	T033	C0581125
27117874	1626	1646	asthma exacerbations	T033	C0349790
27117874	1648	1656	Enhanced	T052	C2349975
27117874	1657	1667	compliance	T033	C3714738
27117874	1672	1683	convenience	T080	C3831015
27117874	1700	1703	use	T169	C0457083
27117874	1707	1720	dexamethasone	T109,T121	C0011777